VJVirtual | Interim results from DESTINY-Lung01: T-DXd in HER2-overexpressing NSCLC

Kazuhiko Nakagawa, MD, PhD, Kindai University Hospital, Osaka, Japan, shares interim results from the HER2-overexpressing cohort of the DESTINY-Lung01 trial (NCT03505710), investigating trastuzumab deruxtecan (T-DXd) in non-small cell lung cancer (NSCLC). T-DXd is a novel HER2-targeted antibody-drug conjugate under investigation in two cohorts in the Phase II DESTINY trial: patients overexpressing HER2 and patients with a HER2-activating mutation. The interim data for the HER2-overexpressing cohort shows T-DXd to be efficacious, with an overall response rate of 24.5% and a disease control rate of 69.4%. Treatment-emergent adverse events caused dose interruption in 53.1% discontinuation in 22.4%. An additional evaluation of a lower dose T-DXd has begun enrollment to further characterize the treatment’s safety and efficacy profile. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.